welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP
“We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug ever to demonstrate a clinical benefit in a randomized, controlled clinical study,” said Pierre Boutouyrie M.D., Ph.D., co-director of the clinical pharmacology service at the Georges-Pompidou European Hospital AP-HP and Principal Investigator for the celiprolol study. “Having established celiprolol as a standard of care in France for vEDS patients, we are excited to partner with Acer to help bring celiprolol to members of the U.S. patient community who are suffering from this devastating, life-threatening disease.”
expertly curated content related to this topic
-
Surgical Management of the Spinal Deformity in Ehlers-Danlos Syndrome Type VIFive patients with Ehlers-Danlos syndrom...
-
Heterogeneity of the Ehlers-Danlos Syndrome: Description of Three Clinical Types and a Hypothesis to Explain the Bas...The Ehlers-Danlos syndrome is an inherit...
-
Henry Burkholder IV, MDDr. Burkholder, a board certified pediat...
-
Joan Marilyn Stoler, MDDr. Joan Stoler specializes in Pediatric...
-
Markus-Frederik Bohn, PHDMarkus-Frederik Bohn, PhD contributes to...
-
Acer Therapeutics and Opexa Therapeutics Sign Merger AgreementOpexa Therapeutics, Inc. (Nasdaq: OPXA) ...
-
Rodney Grahame, CBE, MD, FRCPProfessor Rodney Grahame was a GP in St ...
